The professor of the Barts Cancer Institute of London, Bart Vanhaesebroeck, offered last October 11, in the frame of the IDIBELL Seminars, a summary of his research on the signaling of the PI3 Kinase. Dr. Vanhaesebroeck stressed that he has spent 20 years researching in the field of PI3K, where he began by cloning one of the isoforms (a variant) and is currently participating in the first clinical trials with specific inhibitors for this isoform. Therefore, the presentation of Dr. Vanhaesebroeck stated that his research has been key to establish bridges between basic research and translational research.

Dr. Vanhaesebroeck provided a very complete foresight of the current phase of the research in the signaling pathway of PI3K, both in a physiological context as in different pathologies. The presentation of Dr. Vanhaesebroeck also revealed that although we have made much progress, there are still many unanswered questions and that the research of the coming years will be key to improve current treatments.